With Qynapse we all benefit from earlier and more accurate monitoring of patients.

Patients, practitioners, researchers and you – the payer, all benefit from earlier, more accurate central nervous system disease diagnosis and monitoring of patients throughout the care continuum.

Qynapse has the potential to help lower costs, drive up quality outcomes and improve patient satisfaction. Are you ready to transform neuroscience with us?

Potential to revolutionize diagnosis, care and monitoring of CNS diseases to improve outcomes.

The Qynapse team is on the forefront of neuroimaging and the early prognosis on progress is astounding. Our neuroimaging tool, QyScore®, has been implemented in US and EU clinics and is expanding soon into new global markets and used in multi-site clinical trials and global research collaborations.

When leveraged in a clinical setting, QyScore® provides objective and reliable measures to potentially improve the accuracy of diagnosis, precisely evaluate therapeutic impact and reliably measure disease progression. This also creates the potential for patients to experience a shorter time to diagnosis, fewer clinical visits and a more personalized therapeutic intervention. If these ends are achieved, this may lead to better patient outcomes, improved quality of life, and decreased costs over the CNS care pathway.

Our technology is a game changer.

Our neuroimaging software platform, QyScore®:

  • Provides precise, accurate, objective readouts that may decrease the likelihood of misdiagnosis, which may create transparency to more effectively and efficiently manage patient outcomes
  • Creates the potential for better longitudinal monitoring of disease progression and therapeutic effectiveness, which may help to better manage costs and maximize outcomes
  • Has demonstrated better performance when compared to certain other state-of-the-art automated methods on the market

%

Misdiagnosis Rate

Qynapse provides information to clinicians which may help address the misdiagnosis rate in CNS, which is upwards of 30%

Precise Diagnosis & Monitoring

Qynapse has the potential to help facilitate a more precise diagnosis and monitoring of disease progression

$1 Trillion by 2050

Amongst the most expensive diseases to manage, Alzheimer’s is expected to cost the US healthcare system over $1 trillion by 2050

Bring Qynapse to

your providers.

Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI).

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.

Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.